Temuterkib

LY3214996 (temuterkib) is an ERK1/2 inhibitor that Eli Lilly discovered and ran through a first-in-human Phase 1, then quietly handed off to academic centers. The active trials sit at MD Anderson, Dana-Farber, and Barrow - all investigator-initiated. NCT04616183 paired LY3214996 with cetuximab, optionally adding abemaciclib, in anti-EGFR-refractory metastatic colorectal cancer [1][2]. The bet: hit ERK at the bottom of the MAPK signaling cascade to block the growth signal that drives RAS-mutant tumors and lets colorectal cancers escape EGFR antibodies like cetuximab. Results from the MD Anderson trial were presented at ASCO 2025 (Raghav et al., abstract 3534, n=44): activity was modest, though notably the regimen produced the first reported objective responses to an EGFRi-based combination in patients harboring acquired RAS mutations in pre-rechallenge ctDNA [11]. Lilly has not announced a Phase 3 program, and the molecule's commercial future depends on whether anyone re-engages off these signals.

Novel compound, never approved anywhere. Phase 1b/2 across all active programs. No FDA breakthrough, orphan, fast-track, or priority review designations that we can verify. Lilly's own first-in-human Phase 1 (NCT02857270, n=210) completed in 2024 [3]. The current portfolio is entirely academic: MD Anderson ran the colorectal trial (NCT04616183, ACTIVE_NOT_RECRUITING, n=44 reported at ASCO 2025) [2][11]; Dana-Farber completed an AML monotherapy study (NCT04081259, n=17): no DLTs, no objective responses - 7 progressive disease and 8 stable disease out of 15 evaluable patients per IWG criteria, median time on study 32 days, on-target ERK pathway inhibition confirmed pharmacodynamically but baseline genotype (TP53, AML-MR, RAS) did not correlate with clinical activity [4][12]; a Mayo/DFCI pancreatic trial combined LY3214996 with hydroxychloroquine (NCT04386057, n=52) and published in JCO Precision Oncology in 2025 with modest disease control [5][6]; Barrow Neurological ran a Phase 0/1 in recurrent glioblastoma with abemaciclib (NCT04391595, n=42) [7]. No Phase 3 trial is registered. Lilly itself has gone silent on the molecule in recent earnings calls - a quiet but loud signal about internal priorities.

ERK1 and ERK2 are kinases - enzymes that switch other proteins on by tagging them with phosphate groups. They sit at the bottom of the MAPK cascade, which runs RAS → RAF → MEK → ERK. When RAS or BRAF is mutated and stuck in the 'on' position, the whole pipe fires constantly, and ERK is the final relay that tells the nucleus to keep dividing. In colorectal cancer with KRAS or BRAF mutations, this signal is locked on, which is why EGFR antibodies like cetuximab fail in those patients - the cancer doesn't need the upstream EGFR input anymore. Blocking ERK directly should kill the signal at the bottom, regardless of what mutation lit the pathway upstream [1]. The combination logic in NCT04616183 is non-obvious and worth spelling out: ERK inhibitors can paradoxically trigger a rebound signal through EGFR as a compensatory feedback loop - when ERK is blocked, the cell upregulates EGFR signaling to try to restart the pathway. Cetuximab's role in this regimen is specifically to block that rebound, not to treat EGFR-driven disease directly. This is a different rationale from cetuximab's standard use in RAS-wildtype CRC. Abemaciclib (a CDK4/6 inhibitor) hits the cell cycle in parallel. The genetic case for the pathway is solid - trametinib (a MEK inhibitor one node upstream of ERK) is FDA-approved in BRAF-mutant melanoma and NSCLC. The case for ERK inhibitors specifically is weaker: no ERK inhibitor has been approved anywhere, and ulixertinib, MK-8353, ravoxertinib, and KO-947 have all stalled or been terminated in early-phase trials.

NCT04616183 is a Phase 1b/2 single-center study sponsored by MD Anderson, with 44 patients reported in the ASCO 2025 readout [2][11]. Three arms: LY3214996 plus cetuximab; LY3214996 plus cetuximab plus abemaciclib; expansion in anti-EGFR-refractory unresectable or metastatic colorectal cancer. Primary endpoint is best overall response (complete plus partial response). No randomization, no control arm, no formal head-to-head against standard of care - typical for Phase 1b/2 dose-finding combined with signal-seeking. The patient population in the public ClinicalTrials.gov listing isn't explicitly restricted to RAS-mutant or BRAF-mutant tumors; the protocol document (NCT04616183 ICF/protocol on ClinicalTrials.gov) requires anti-EGFR refractoriness, and the ASCO 2025 readout was framed around acquired RAS mutations detected in pre-rechallenge ctDNA - so the design effectively enriched for acquired-resistance biology even without formal mutational selection. Status ACTIVE_NOT_RECRUITING means enrollment is closed and patients are on follow-up. Forty-four patients across three arms means roughly 15 per arm - too small to call efficacy with confidence, and the ASCO 2025 data confirm that signal-seeking arithmetic: activity was modest in the pooled analysis. The companion preclinical work from Frank et al. showed a SHP2 inhibitor (RMC-4550) plus LY3214996 worked in KRAS-mutant pancreatic models, which suggests SHP2 combinations might have been a better partner than cetuximab for the broader RAS-driven population [8].

The model gives this drug a 7% chance of eventually being approved. That starts from the historical approval rate for Phase 2 drugs in this area - about 13% - then adjusts up or down based on ten facts about the trial and sponsor. The trial's non-randomized design and open-label blinding push the estimate up, while the sponsor's thin approval record and weak earlier-phase results pull it down. The remaining factors are close to average for this stage, so they leave the number roughly where it started.

Efficacy is the dominant risk and the ASCO 2025 readout from NCT04616183 confirmed it: activity was modest in pooled analysis even with a mechanistically sensible cetuximab combination [11]. ERK inhibitors hit a validated pathway but historically deliver single-digit to teens response rates as monotherapy, and combination strategies haven't cleared the bar that MEK inhibitors set in melanoma. The Dana-Farber AML monotherapy data (0 ORR, 7 PD vs 8 SD out of 15 evaluable) reinforce the single-agent ceiling [12]. Safety is the second risk: ERK inhibition causes the same on-target dermatologic toxicities as MEK inhibitors - rash, paronychia, mucositis, diarrhea - and the NCT04616183 ASCO 2025 readout reported grade 3 treatment-related adverse events in 31.8% (14/44), most commonly acneiform rash (9.1%), diarrhea (9.1%), thrombocytopenia (6.8%), fatigue (4.5%), and anemia (4.5%), with one grade 4 thrombocytopenia [11]. Cetuximab itself causes acneiform rash, so the combination stacks skin toxicity on skin toxicity. Adding abemaciclib piles on neutropenia and diarrhea. Execution risk is structural: investigator-initiated, small N, no central randomization, single site. Any positive signal will need a Lilly-sponsored confirmatory trial that may never get funded. Commercial risk is the kill shot. Even if the acquired-RAS-mutant ctDNA signal holds up, Lilly's apparent deprioritization means there may be no sponsor to bring this to market. The molecule has no orphan designation, no breakthrough therapy status, no public Phase 3 plan. Patent/exclusivity status for LY3214996 is not publicly disclosed in Lilly investor materials we could verify; any licensing decision by a third party would hinge on remaining composition-of-matter coverage that we cannot confirm from the public record.

Watch, don't lean in - and most of the watching is already done. NCT04616183 read out at ASCO 2025 (Raghav et al., abstract 3534), not at a future ASCO GI: activity was modest in the pooled n=44 population, though the regimen produced the first reported objective responses to an EGFRi-based combination in patients with acquired RAS mutations detected in pre-rechallenge ctDNA [11]. That's a real but narrow signal - a niche-resistance-population finding, not a broad CRC win. The pancreatic results from NCT04386057 are already public - disease control was modest and not a breakout [5]. The Dana-Farber AML monotherapy trial closed with zero objective responses [12]. KO-947 (Kura) was terminated before expansion cohorts with best response of stable disease, joining MK-8353 and ravoxertinib in the discontinued-ERK-inhibitor pile [13]. The remaining catalyst window is ESMO 2026 (October) for any updated NCT04616183 follow-up or biomarker-stratified subgroup analysis. Lilly (LLY) doesn't need this molecule to work; Lilly's R&D capital is dominated by tirzepatide and retatrutide in metabolic disease - ERK1/2 inhibition is not a strategic priority in any active Lilly franchise. The chemistry is real, the PK is real (CSF penetration was characterized in the GBM trial [10]), but the commercial home is missing. Move to passive monitoring; flag only if a biopharma licenses the asset off the acquired-RAS-mutant ctDNA niche.